First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC
Phase III Study Being Initiated For Two-Drug Regimen
Executive Summary
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.
You may also be interested in...
ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC
A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.
ESMO: Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race
The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.
Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial
Amgen said its KRAS G12C inhibitor Lumakras (sotorasib) bested docetaxel in a Phase III clinical trial on the primary endpoint of progression-free survival in second-line-plus non-small cell lung cancer.